422 related articles for article (PubMed ID: 29617666)
21. A comprehensive characterization of
Shiraishi Y; Kataoka K; Chiba K; Okada A; Kogure Y; Tanaka H; Ogawa S; Miyano S
Genome Res; 2018 Aug; 28(8):1111-1125. PubMed ID: 30012835
[TBL] [Abstract][Full Text] [Related]
22. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors.
Arnold JM; Choong DY; Thompson ER; ; Waddell N; Lindeman GJ; Visvader JE; Campbell IG; Chenevix-Trench G
Breast Cancer Res Treat; 2010 Jan; 119(2):491-6. PubMed ID: 19189213
[TBL] [Abstract][Full Text] [Related]
23. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
[TBL] [Abstract][Full Text] [Related]
24. Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5' splice-site disruption.
Wimmer K; Roca X; Beiglböck H; Callens T; Etzler J; Rao AR; Krainer AR; Fonatsch C; Messiaen L
Hum Mutat; 2007 Jun; 28(6):599-612. PubMed ID: 17311297
[TBL] [Abstract][Full Text] [Related]
25. Synonymous mutations frequently act as driver mutations in human cancers.
Supek F; Miñana B; Valcárcel J; Gabaldón T; Lehner B
Cell; 2014 Mar; 156(6):1324-1335. PubMed ID: 24630730
[TBL] [Abstract][Full Text] [Related]
26. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
Pettitt SJ; Krastev DB; Brandsma I; Dréan A; Song F; Aleksandrov R; Harrell MI; Menon M; Brough R; Campbell J; Frankum J; Ranes M; Pemberton HN; Rafiq R; Fenwick K; Swain A; Guettler S; Lee JM; Swisher EM; Stoynov S; Yusa K; Ashworth A; Lord CJ
Nat Commun; 2018 May; 9(1):1849. PubMed ID: 29748565
[TBL] [Abstract][Full Text] [Related]
27. Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies.
Oppel F; Tao T; Shi H; Ross KN; Zimmerman MW; He S; Tong G; Aster JC; Look AT
PLoS Genet; 2019 Apr; 15(4):e1008039. PubMed ID: 30970016
[TBL] [Abstract][Full Text] [Related]
28. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
[TBL] [Abstract][Full Text] [Related]
29. Pervasive occurrence of splice-site-creating mutations and their possible involvement in genetic disorders.
Sakaguchi N; Suyama M
NPJ Genom Med; 2022 Mar; 7(1):22. PubMed ID: 35304488
[TBL] [Abstract][Full Text] [Related]
30. BRCA1/2 germline missense mutations: a systematic review.
Corso G; Feroce I; Intra M; Toesca A; Magnoni F; Sargenti M; Naninato P; Caldarella P; Pagani G; Vento A; Veronesi P; Bonanni B; Galimberti V
Eur J Cancer Prev; 2018 May; 27(3):279-286. PubMed ID: 28277317
[TBL] [Abstract][Full Text] [Related]
31. Characterization of germline TP53 splicing mutations and their genetic and functional analysis.
Varley JM; Attwooll C; White G; McGown G; Thorncroft M; Kelsey AM; Greaves M; Boyle J; Birch JM
Oncogene; 2001 May; 20(21):2647-54. PubMed ID: 11420676
[TBL] [Abstract][Full Text] [Related]
32. GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.
Shan L; Li X; Liu L; Ding X; Wang Q; Zheng Y; Duan Y; Xuan C; Wang Y; Yang F; Shang Y; Shi L
Oncogene; 2014 Jun; 33(24):3205-16. PubMed ID: 23851505
[TBL] [Abstract][Full Text] [Related]
33. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs.
Vreeswijk MP; Kraan JN; van der Klift HM; Vink GR; Cornelisse CJ; Wijnen JT; Bakker E; van Asperen CJ; Devilee P
Hum Mutat; 2009 Jan; 30(1):107-14. PubMed ID: 18693280
[TBL] [Abstract][Full Text] [Related]
34. PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3.
Ding L; Chen X; Xu X; Qian Y; Liang G; Yao F; Yao Z; Wu H; Zhang J; He Q; Yang B
Cancer Immunol Res; 2019 Jan; 7(1):136-149. PubMed ID: 30401677
[TBL] [Abstract][Full Text] [Related]
35. Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.
Xing D; Liu Y; Park HJ; Baek I; Tran H; Cheang G; Novo J; Dillon J; Matoso A; Farmer E; Cheng MA; Tsai YC; Lombardo K; Conner MG; Vang R; Hung CF; Wu TC; Song W
Hum Pathol; 2019 Oct; 92():67-80. PubMed ID: 31437519
[TBL] [Abstract][Full Text] [Related]
36. Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort.
Akter H; Sultana N; Martuza N; Siddiqua A; Dity NJ; Rahaman MA; Samara B; Sayeed A; Basiruzzaman M; Rahman MM; Rashidul Hoq M; Amin MR; Baqui MA; Woodbury-Smith M; Uddin KMF; Islam SS; Awwal R; Berdiev BK; Uddin M
BMC Med Genet; 2019 Sep; 20(1):150. PubMed ID: 31477031
[TBL] [Abstract][Full Text] [Related]
37. Pan-cancer repository of validated natural and cryptic mRNA splicing mutations.
Shirley BC; Mucaki EJ; Rogan PK
F1000Res; 2018; 7():1908. PubMed ID: 31275557
[TBL] [Abstract][Full Text] [Related]
38. Analysis of splice-site mutations of the alpha-galactosidase A gene in Fabry disease.
Lai LW; Whitehair O; Wu MJ; O'Meara M; Lien YH
Clin Genet; 2003 Jun; 63(6):476-82. PubMed ID: 12786754
[TBL] [Abstract][Full Text] [Related]
39. The effect of disease-associated HRPT2 mutations on splicing.
Hahn MA; McDonnell J; Marsh DJ
J Endocrinol; 2009 Jun; 201(3):387-96. PubMed ID: 19332451
[TBL] [Abstract][Full Text] [Related]
40.
Biton J; Mansuet-Lupo A; Pécuchet N; Alifano M; Ouakrim H; Arrondeau J; Boudou-Rouquette P; Goldwasser F; Leroy K; Goc J; Wislez M; Germain C; Laurent-Puig P; Dieu-Nosjean MC; Cremer I; Herbst R; Blons H; Damotte D
Clin Cancer Res; 2018 Nov; 24(22):5710-5723. PubMed ID: 29764856
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
